NCT04624399View on ClinicalTrials.gov

Neoadjuvant Immune Checkpoint Inhibitor Treatment in Urothelial Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

June 17, 2021

Primary Completion Date

May 30, 2026

Study Completion Date

May 30, 2026

Conditions
Urogenital Cancer
Interventions
DRUG

Atezolizumab

Patients receive 2 x 3-weekly cycles of Atezolizumab (one infusion on the first day of each cycle) prior to cystectomy surgery.

Trial Locations (1)

Unknown

RECRUITING

Barts and London Hospital NHS Trust, London

All Listed Sponsors
collaborator

Hoffmann-La Roche

INDUSTRY

lead

Queen Mary University of London

OTHER